comparemela.com

Page 12 - Marie Galay News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Calliditas Therapeutics: Calliditas provides a regulatory update on EMA process for Nefecon

STOCKHOLM, March 22, 2022 /PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the opinion of the Committee for Medicinal Products

United statesMarie galayExchange commissionEuropean medicines agencyCommittee for medicinal products human useNasdaq stockholmMedicinal productsHuman useAmerican depositary sharesNasdaq global select marketPrivate securities litigation reform act

Calliditas Therapeutics: Updated regulatory plans for NEFECON in China

STOCKHOLM, March 18, 2022 /PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that partner Everest Medicines (HKEX 1952.HK) plans

United statesSouth koreaMarie galayExchange commissionEuropean medicines agencyNational medical products administrationChina centerNasdaq stockholmEverest medicinesBreakthrough therapy designationDrug evaluationGreater chinaIga nephropathyAmerican depositary sharesNasdaq global select marketPrivate securities litigation reform act

Updated regulatory plans for NEFECON in China

/PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that partner Everest Medicines (HKEX 1952.HK).

United statesSouth koreaMarie galayExchange commissionEuropean medicines agencyNational medical products administrationChina centerNasdaq stockholmEverest medicinesBreakthrough therapy designationDrug evaluationGreater chinaIga nephropathyAmerican depositary sharesNasdaq global select marketPrivate securities litigation reform act

Updated regulatory plans for NEFECON in China

/PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that partner Everest Medicines (HKEX 1952.HK).

United statesSouth koreaMarie galayExchange commissionEuropean medicines agencyNational medical products administrationChina centerNasdaq stockholmEverest medicinesBreakthrough therapy designationDrug evaluationGreater chinaIga nephropathyAmerican depositary sharesNasdaq global select marketPrivate securities litigation reform act

Expansion of Everest Medicine s licence agreement to include South Korea

/PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has expanded its licensing.

South koreaMarie galayExchange commissionEuropean medicines agencyEverest medicines ii limitedNasdaq stockholmEverest medicinesGreater chinaIga nephropathyNasdaq global select marketPrivate securities litigation reform actCalliditas therapeutics

vimarsana © 2020. All Rights Reserved.